Unknown PHASE2 INTERVENTIONAL 2-arm NCT02561546

p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma

A Phase II Study to Investigate Preliminary Efficacy Using p53 Gene Therapy for Treatment of Diabetes Concurrent With Hepatocellular Carcinoma

Sponsor: Shenzhen SiBiono GeneTech Co.,Ltd

Conditions Diabetes HCC

Interventions Trans-catheter embolization p53 gene therapy

Updated 6 times since 2017 Last updated: Sep 25, 2015 Started: Dec 31, 2015 Primary completion: Oct 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02561546, this PHASE2 trial focuses on Diabetes and HCC and remains ongoing. Sponsored by Shenzhen SiBiono GeneTech Co.,Ltd, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen SiBiono GeneTech Co.,Ltd

Data source: Shenzhen SiBiono GeneTech Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dalian, China